Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use LIFYORLI safely and effectively. See full prescribing information for LIFYORLI. LIFYORLITM (relacorilant) capsules, for oral useInitial U.S. Approval: 2026
Medication labelWhy this: Advisory · dailymed-prescription
LIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab [see Clinical Studies (14)].
- generic_name
- relacorilant
- product_names
- Relacorilant
- ndc
- 76346-425, 76346-425-11, 76346-425-01, 76346-025, 76346-025-01, 76346-100, 76346-100-01, 76346-525, 76346-525-33, 76346-525-03, 76346-525-09, 76346-450, 76346-450-11, 76346-450-01, 76346-550, 76346-550-33, 76346-550-03, 76346-550-09
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en